Navigation Links
Study opens new prospects for developing new targeted therapies for breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

This current study was led by Dr Martine Piccart, Director of Medicine at the Jules Bordet Institute in Brussels, and Dr Jose Baselga, Associate Director at Memorial Sloan-Kettering Cancer Center, New York.

The researchers used modern sequencing technology to characterise the genetic aberrations of cancer genes present in tumour samples from a well-defined cohort of advanced postmenopausal patients who were enrolled in the BOLERO-2 clinical trial.

"The results of this study generated hypotheses for developing more rational targeted therapy combinations based on the specific genetic aberrations present in each individual tumour," Dr Piccart said.

"This work, together with previous works published last year, highlights again the genetic heterogeneity of breast cancer. These results show that tumours that may look very similar at the clinical level, can be genetically very different, suggesting that they may require different treatment strategies."

"There is still a long way to go before we will be able to offer truly personalised therapies to cancer patients, and support for research such as this will be critical to accelerate this process," Dr Piccart said.

The study involved postmenopausal women with advanced breast cancer that was hormone receptor positive and HER2 negative taking part in the BOLERO-2 phase III trial. The trial showed that everolimus plus exemestane significantly improved progression-free survival, response rate and clinical benefi
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Law that regulates shark fishery is too liberal: UBC study
3. New study will help protect vulnerable birds from impacts of climate change
4. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
5. BYU study: Using a gun in bear encounters doesnt make you safer
6. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Crystal structure of archael chromatin clarified in new study
9. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
10. University of Houston study shows BP oil spill hurt marshes, but recovery possible
11. Study demonstrates cells can acquire new functions through transcriptional regulatory network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... birth weight and preterm birth are linked to increased ... published in the American College of Rheumatology (ACR) journal, ... birth weight and pre-term babies were not at greater ... , According to the ACR, 27 million Americans ... OA. Symptoms of OA range from mild to severe ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
... long been considered a major risk factor for cardiovascular ... risk, but the mechanisms of how arteries stave off ... the Perelman School of Medicine, University of Pennsylvania, Wistar ... that the protein apolipoprotein E (apoE) plays a major ...
... the Nowgen Schools Genomics Programme website launches with a range ... genetics in schools and colleges. , Developments in genetics research ... at a cost of $3 billion to sequencing a genome ... genetics in classroom education have remained relatively static. The pace ...
... Research led by Chu Chen, PhD, Associate Professor of Neuroscience ... enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target ... online November 1, 2012 in the Online Now section of ... that inactivation of MAGL, best known for its role in ...
Cached Biology News:Softening arteries, protecting the heart 2Softening arteries, protecting the heart 3Bridging the gap between genomics and education 2LSUHSC research identifies new therapeutic target for Alzheimer's disease 2
(Date:11/21/2014)... The California Healthcare Institute ... representing leading California academic institutions, biotechnology, medical device, ... today released a report revealing that California ... The trend shows a 4 percent increase between ... Industry Report indicates that, while biopharmaceutical and ...
(Date:11/21/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Sodium ferrocyanide ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... month periods ended September 30, 2014.  Biorem,s complete 2014 third quarter ... ). Financial Summary:Three-months ended September 30, , ... share data) , 2014 , 2013 ... , 5,281 , 6,715 , ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... , COLUMBIA, Md., Sept. 8 Martek Biosciences ... of judges on the United States Court of Appeals for the ... to a patent infringement lawsuit between Martek and Lonza, Ltd., Nutrinova ... The appeals involve Lonza,s U.S. sale and use of DHA ...
... $5 Million Loan Will Leverage $15 Million ... , HARRISBURG, Pa., Sept. 8 Early-stage life ... create quality jobs with the help of a state investment in ... "The life sciences are a growth sector for Pennsylvania," ...
... Inc. (TSX: ONC, NASDAQ: ONCY ), will present ... Renshaw 11th Annual Healthcare Conference on Thursday, September 10, ... at the New York Palace Hotel from September 9 to ... will be available at: http://www.wsw.com/webcast/rrshq15/oncy or on the ...
Cached Biology Technology:Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 2Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 3PA Helping Life Science Companies Secure Venture Capital Needed to Expand, Gov. Rendell Says 2Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference 2
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
BACE (CT) rabbit polyclonal antibody...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: